New Therapies for Asthma: What Else Besides Steroids?
Pp. 24-49 (26)
Jorge Sánchez and Javier Estarita
Allergic disorders are a group of multifactorial diseases increasing in
prevalence in recent years. Steroids remain the cornerstone of symptomatic treatment,
but advances in molecular biology have led to a better understanding of the
pathogenesis of allergic diseases and multiple medications; especially monoclonal
antibodies have been developed with different therapeutic targets.
Omalizumab (Anti-IgE) and mepolizumab (Anti-IL5) are some of the biological agents
already available for the treatment of asthma and other allergic diseases, but many other
molecules are currently being studied in clinical trials. In this chapter we review the
different monoclonal antibodies that are being studied in allergic diseases with emphasis
on the evidence of their use in asthma.
Asthma, allergy, allergen, immunotherapy, immunomodulation,
monoclonal antibodies, mepolizumab, omalizumab, immunoglobulin,
GACE, Group of Clinical and Experimental Allergy, University of Antioquia, (Medellín - Colombia).